{"id":"mk5172-mk8742","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3823406","moleculeType":"Small molecule","molecularWeight":"882.03"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MK5172 (grazoprevir) inhibits the NS3/4A serine protease essential for HCV polyprotein processing, while MK8742 (elbasvir) inhibits the NS5A protein required for viral RNA replication and virion assembly. Together, these direct-acting antivirals target multiple steps of the HCV lifecycle to achieve sustained virologic response.","oneSentence":"MK5172/MK8742 is a combination of a hepatitis C virus NS3/4A protease inhibitor and an NS5A inhibitor that blocks viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:45.291Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype 1, 4, 6)"}]},"trialDetails":[{"nctId":"NCT02940496","phase":"PHASE2","title":"Pembrolizumab (MK-3475) in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-12-09","conditions":"BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection","enrollment":15},{"nctId":"NCT02613403","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-10","conditions":"Hepatitis, Hepatitis C, Digestive System Diseases","enrollment":94},{"nctId":"NCT03379506","phase":"PHASE2","title":"Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-01-25","conditions":"HCV Infection","enrollment":57},{"nctId":"NCT02823457","phase":"NA","title":"VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"G.V. (Sonny) Montgomery VA Medical Center","startDate":"2017-04-05","conditions":"Patient Adherence, Chronic Hepatitis C, Alcohol-related Disorders","enrollment":20},{"nctId":"NCT02133131","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-13","conditions":"Hepatitis C","enrollment":143},{"nctId":"NCT02105701","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Hepatitis C Infection","enrollment":420},{"nctId":"NCT02105662","phase":"PHASE3","title":"An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-03","conditions":"Chronic Hepatitis C","enrollment":218},{"nctId":"NCT01717326","phase":"PHASE2","title":"A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-07","conditions":"Hepatitis C","enrollment":573},{"nctId":"NCT01932762","phase":"PHASE2","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-01","conditions":"Hepatitis C","enrollment":98},{"nctId":"NCT04546802","phase":"PHASE3","title":"HepATocellular Cancer Hcv Therapy Study","status":"WITHDRAWN","sponsor":"Bayside Health","startDate":"2019-09","conditions":"Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma","enrollment":""},{"nctId":"NCT03111108","phase":"PHASE4","title":"Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-06-20","conditions":"Hepatitis C Virus (HCV) Infection","enrollment":117},{"nctId":"NCT02105688","phase":"PHASE3","title":"An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-02","conditions":"Chronic Hepatitis C","enrollment":301},{"nctId":"NCT02601573","phase":"PHASE2","title":"Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-05","conditions":"Hepatitis C","enrollment":101},{"nctId":"NCT02332720","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-01-28","conditions":"Hepatitis C","enrollment":413},{"nctId":"NCT02332707","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-01-22","conditions":"Hepatitis C","enrollment":443},{"nctId":"NCT02600325","phase":"PHASE3","title":"Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2016-02","conditions":"Acute Hepatitis C, Human Immunodeficiency Virus, Hepatitis C","enrollment":80},{"nctId":"NCT02115321","phase":"PHASE2, PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-09","conditions":"Chronic Hepatitis C","enrollment":40},{"nctId":"NCT01937975","phase":"PHASE1","title":"The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-06","conditions":"Chronic Hepatitis C, Renal Impairment","enrollment":24},{"nctId":"NCT02897596","phase":"PHASE3","title":"Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2017-04-28","conditions":"Hepatitis C, HIV","enrollment":62},{"nctId":"NCT02251990","phase":"PHASE3","title":"Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-01-28","conditions":"Hepatitis C","enrollment":489},{"nctId":"NCT02358044","phase":"PHASE3","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT02252016","phase":"PHASE3","title":"Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-10-22","conditions":"Hepatitis C","enrollment":159},{"nctId":"NCT02105467","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Chronic Hepatitis C Virus","enrollment":421},{"nctId":"NCT02105454","phase":"PHASE2","title":"Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"Hepatitis C Virus","enrollment":79},{"nctId":"NCT02092350","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-17","conditions":"Hepatitis C Virus","enrollment":237},{"nctId":"NCT02203149","phase":"PHASE2, PHASE3","title":"Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-01","conditions":"Hepatitis C","enrollment":399},{"nctId":"NCT03433326","phase":"","title":"Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy","status":"UNKNOWN","sponsor":"University of Florence","startDate":"2018-03-01","conditions":"Hepatitis C, Cryoglobulinaemic Glomerulonephritis","enrollment":45},{"nctId":"NCT02732405","phase":"PHASE3","title":"Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis","status":"UNKNOWN","sponsor":"Istituto Clinico Humanitas","startDate":"2016-05","conditions":"Hepatitis C, Compensated Cirrhosis","enrollment":120},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK5172 /MK8742","genericName":"MK5172 /MK8742","companyName":"Istituto Clinico Humanitas","companyId":"istituto-clinico-humanitas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK5172/MK8742 is a combination of a hepatitis C virus NS3/4A protease inhibitor and an NS5A inhibitor that blocks viral replication. Used for Chronic hepatitis C virus infection (genotype 1, 4, 6).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}